News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
About the Author - Mark Terry

news@biospace.com

BioSpace News - By Mark Terry
How BioMarin (BMRN)'s Model for Super-Rare Diseases Made It a $15 Billion Powerhouse 7/29/2016
A Look at Four Biotech Giants' Q2 Earnings 7/29/2016
AstraZeneca PLC (AZN) CEO Stays Mum as Rumors Swirl Over a Possible Novartis AG (NVS) Takeover Bid 7/28/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
Brexit Schmexit: What This Mess Means for Life Science Jobs 7/28/2016
Pfizer (PFE) Wins Bid; Buys BIND Therapeutics (BIND) Bankruptcy Assets for $40 Million 7/27/2016
Flushed With Cash, Moderna Expands Space, Went on Hiring Spree and Launches at Least Two Clinical Trials 7/27/2016
Post-Brexit, GlaxoSmithKline (GSK) Eyes Jobs Boost With $360 Million Investment in Three UK Manufacturing Sites 7/27/2016
Why Investors are Still Throwing Cash at Debt-Ridden Kadmon, a NYC Biotech Founded By Ex-Con Sam Waksal 7/26/2016
Speculation Heats Up on Biogen (BIIB) as an Acquisition Target or Starting a Buying Spree 7/26/2016
pSivida (PSDV) Has Its Own Brexit, Consolidates U.K. Operations to Massachusetts HQ 7/26/2016
Bankrupt BIND Therapeutics (BIND) Reveals Two More Bidders Join Pfizer (PFE)'s Stalking Horse Bid 7/26/2016
5 Biotech Stocks on the Brink of Breaking Out 7/25/2016
As Biogen (BIIB) Boss Moves to the Bay Area, California Biotechs Pay Attention 7/25/2016
A Look at Who Could Buy Gilead (GILD) and Who Gilead Should Buy 7/25/2016
Biogen (BIIB) CEO Steps Down Amid Stellar Q2 Financials, Hunt for New Leader Begins 7/22/2016
Amid Trial Concerns, FDA Delays Approval Decision for Merck & Co. (MRK)'s C. Diff Drug, New PDUFA Date Set 7/22/2016
Why Investors Should Pay Attention to Seattle Genetics (SGEN)' Drug Trial 7/22/2016
3 Battered Biopharma Stocks Battling to Recover 7/22/2016
Zafgen (ZFGN) Pinks Slips 34% of Workforce, Scraps Lead Obesity Drug After Deaths 7/21/2016
AstraZeneca PLC (AZN) Announces MedImmune (AZN) Layoffs, But Does Not Specify Numbers or Location 7/21/2016
Cambridge Startup Jounce Lands $2.5 Billion Deal With Biotech's Best Friend Celgene (CELG) 7/20/2016
Former bluebird bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A 7/20/2016
Zafgen (ZFGN)'s Alicia Secor Steps Up as Juniper Pharma (JNP)’s President and CEO 7/20/2016
Johnson & Johnson (JNJ)'s CFO Talks M&A Strategy, Doesn’t Rule Out Acquisitions 7/20/2016
Bay Area's SciClone (SCLN) Abandons Sale Strategy 7/19/2016
Examining Pfizer (PFE)’s Strategic Options-Split Up or Start Buying 7/19/2016
Why 5 Big Pharma’s Struggle to Please Investors 7/19/2016
3 Biotech Stocks for the Conservative Investor 7/18/2016
Juno (JUNO) Stock Falls Again After Correcting Number of Trial Deaths 7/18/2016
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths 7/18/2016
The ROI of Gratitude: Two Biotechs Getting It Right 7/18/2016
Merck & Co. (MRK) to Cut or Shift 360 East Coast Jobs, Add 100 in the Bay Area 7/15/2016
With a Strong Cancer Presence and Pipeline, Incyte (INCY) Would Make a Sweet Acquisition 7/15/2016
With Little Fanfare, Biogen (BIIB) Sneaks Lupus Drug Into a Phase I Trial 7/15/2016
SAGE Therapeutics (SAGE)' Stock Explodes as Drug Eliminates Postpartum Depression in Mid-Stage Study 7/14/2016
Former Biogen (BIIB) Exec to Head Decibel Therapeutics, Plans to Fill 20 Jobs This Year, 40 to 60 in 2017 7/14/2016
Life Science Job Market in Washington State Heats Up as Juno (JUNO) and Seattle Genetics (SGEN) Hire 250+ 7/14/2016
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016
Juno (JUNO) Soars After the FDA OKs Restart of Clinical Trial 7/14/2016
Bay Area's Second Genome Taps New CEO, Series B Financing Expanded to $51 Million 7/14/2016
Sanofi (SNY) Hunts Other Oncology Companies for Cancer Gold 7/13/2016
San Diego's Sorrento (SRNE) Forges €735 Million Immuno-Onco Tie-Up with Servier 7/12/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths 7/11/2016
Japan's Nichi-Iko Takes Out Sagent Pharma for $736 Million Cash 7/11/2016
As Shire (SHPG) Closes on Baxalta (BXLT), David Meek Takes the Helm at Ipsen (IPN.PA) 7/11/2016
How Gilead (GILD) Is Built Like Apple (AAPL) 7/11/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data 7/8/2016
Pernix (PTX) Axes 23% of Workforce in Restructuring to Save $10 Million Annually 7/7/2016
Cempra (CEMP) Stashes Cash to Focus on Marketing Its New Anti-Bacterial Once FDA Gives It Thumb’s-Up 7/7/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine 7/7/2016
Gilead (GILD)'s Strategy for New Hep C Drug Epclusa 7/7/2016
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology 7/6/2016
With Jobs at Stake, Medivation (MDVN) Inks Confidentiality Deals With Sanofi (SNY), Pfizer (PFE) and Celgene (CELG) 7/6/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Bristol-Myers Squibb (BMY) Scoops Up Swedish Firm Cormorant in $520 Million Deal 7/6/2016
Arena (ARNA) Drops Bombshell on its Workforce by Cutting 73% of Jobs 7/6/2016
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda (TKPYY) 7/6/2016
Only Days After Inking Asset Swap Deal With Sanofi (SNY), Boehringer Ingelheim Cuts 725 Jobs in the U.S. 7/5/2016
Tesaro (TSRO) Stock Soars as Acquisition Rumors Swirl After Excellent Phase III Results 7/5/2016
AstraZeneca PLC (AZN), Valeant (VRX) and LEO Pharma Shuffle Dermatology Rights, Potential $1 Billion in Sales at Stake 7/5/2016
With Investments from Pfizer (PFE) and AbbVie (ABBV), Morphic Therapeutic Closes a $51.5 Million Series A Round 7/1/2016
3 Biopharma Stocks That Have Taken a Lickin & Kept on Tickin 7/1/2016
Check Out These 3 Solid Biotech Stocks That Are Currently Undervalued 7/1/2016
Fibrocell (FCSC) Looking for Azficel-T Buyer and Lays Off Employees as Program Winds Down 7/1/2016
3 Bargain Basement Biotech Stocks That Have the Potential to Skyrocket 6/30/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
As Stock Rises and Baxalta (BXLT) Merger Closes, Shire (SHPG) Opens New HQ in Massachusetts with 800 Jobs 6/30/2016
Investors Gain Focus as Shire (SHPG) Stock Rises at Positive ADHD Drug News 6/30/2016
How Amgen (AMGN) Fits Into Pfizer (PFE)’s Restructuring Plans 6/30/2016
Israel’s Kaiima Bio-Agritech Ltd. Expands U.S. Operations in St. Louis 6/29/2016
In Light of Two Major Failed Trials, FORUM Pharma Closes Its Doors This Week 6/29/2016
CRO Veristat Plans Expansion in Research Triangle Area, To Hire 150 Or More Starting Now 6/29/2016
Biotech Startup Immage Biotherapeutics (IMMG) Gets Ready for Philadelphia Expansion 6/28/2016
Sanofi (SNY) Inks Deal to Swap Business with Boehringer Ingelheim 6/28/2016
Mayne Pharma Expands into U.S. Through the $652 Million Acquisition of 42 Generic Drugs From Allergan (AGN) and Teva (TEVA) 6/28/2016
Bristol-Myers Squibb (BMY)'s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation 6/28/2016
How Brexit Is Affecting UK’s Drug Companies, Including GlaxoSmithKline (GSK), Gilead (GILD) and AstraZeneca PLC (AZN) 6/28/2016
NewLink Genetics (NLNK) Stock Slides and Company Lays Off 87 After Failed Trial 6/28/2016
Pfizer (PFE)’s $200 Million Facility in Massachusetts Will Create 75 Permanent Jobs 6/22/2016
5 Biotech Stocks at Bargain Basement Prices 6/22/2016
Epizyme (EPZM) to Continue Blood Cancer Trials as Tumors Were Wiped Out in Some Patients 6/21/2016
Bay Area's IMPAX Labs (IPXL) Plunks Down $586 Million for a Chunk of Teva (TEVA) and Allergan (AGN)’s Generics Portfolio 6/21/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
Selecta's IPO Expected Next Week; Sixth Biotech in Massachusetts to Go Public This Year 6/20/2016
Stock Pop Gives Hints that GlobeImmune (GBIM) Might Be Fielding Takeover Offers 6/20/2016
As Monsanto  (MON) Bid Stalls, Bayer AG (BAYZF) Mulls Sale of $3 Billion Radiology Business 6/20/2016
4 Movers & Shakers in This Year’s Oncology Market 6/20/2016
If Spurned By Medivation (MDVN), Sanofi (SNY) May Turn to BioMarin (BMRN) for a Little Love 6/17/2016
BioMarin (BMRN) Stock Wobbles After Hemophilia A Trial Suspended 6/17/2016
Inside the Biotech Employer's Head: Job Interview Questions That You Should Be Ready to Answer 6/16/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
3 Battered and Bruised Life Science Stocks Ready for a Comeback 6/16/2016
Perrigo (PRGO) Stock Spikes on Rumors of Mystery UK Company’s $20 Billion Acquisition Bid 6/15/2016
Looking at the Odds, Pfizer (PFE), Incyte (INCY) or Merck & Co. (MRK) Will Gobble Up Tiny Agenus (AGEN) 6/14/2016
Amid Insider Trader Investigations, Acucela (AUCL) and Otsuka Pharma Kill Glaucoma Drug Deal After Failed Trial 6/14/2016
Bay Area's diaDexus Files Chapter 7 Bankruptcy, Plans to Liquidate Assets, CFO to Step Down Immediately 6/14/2016
Unclear Whether FDA Took Into Account KemPharm (KMPH)'s Amendment Data in Rejecting Apadaz Application 6/14/2016
Once Floated as Allergan (AGN) Target, Revance (RVNC)'s Stock Drops as Crow’s Feet Drug Fails Trial 6/14/2016
5 Biotech Stocks for Investors Who Want Long-Term Returns 6/13/2016
Sam Waksal, Part of the Martha Stewart Insider Trading Scandal, Exits Kadmon as Company Files for $115 Million IPO 6/13/2016
3 Life Science Stocks Millennials Should Watch Over the Long Haul 6/10/2016
Amid Plunging Stocks and Failed Trials, Biogen (BIIB)’s CIO Quietly Leaves Company 6/10/2016
Days After Judge Overturns Merck & Co. (MRK)-Gilead (GILD) Lawsuit, Merck Acquires Bay Area's Afferent Pharma for $1.2 Billion 6/10/2016
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016
BIO2016: The State of the Biotech Innovation and Drivers of Forecasting Success 6/9/2016
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine 6/9/2016
Biogen (BIIB) Loses $8 Billion in Market Value in One Day After Failed Trial 6/8/2016
BIO2016: Where the Bioscience Jobs Are and the Current Trends 6/8/2016
FDA Questions Merck & Co. (MRK)'s C. Diff Diarrhea Medication’s Efficacy 6/8/2016
Rho's Mission to Headhunt for New Employees at DIA 2016 6/8/2016
Allergan (AGN) CEO Dishes on Strategy and Some Of His Battles Over Deals And Mergers 6/7/2016
Sarepta (SRPT) Surges Yet Again, as the FDA Requests More Data About Duchenne’s Drug 6/7/2016
Former Pfizer (PFE) Employee and Childhood Friend Busted on Insider Trading Scheme 6/7/2016
Former Medivation (MDVN) CMO Takes Helm at Roivant Sciences-Takeda (TKPYY)'s Newly Launched Company Myovant Sciences 6/6/2016
ASCO2016: AbbVie (ABBV) Pushes R&D, While Stemcentrx's Lung Cancer Drug Shows Early Promise 6/6/2016
ASCO2016: After NantHealth (NH) Explodes onto the Market, Patrick Soon-Shiong Prepares for Two More 6/6/2016
Rumors Floating Again that Roche (RHHBY) or GlaxoSmithKline (GSK) Might Acquire Bay Area’s Pacific Biosciences (PACB) 6/3/2016
Pfizer (PFE) Boss Discusses M&A Strategy and Says No to Tax Inversions 6/3/2016
Patrick Soon-Shiong's NantHealth (NH) Explodes onto Market in IPO Debut 6/3/2016
Why Sanofi (SNY) is So Infatuated With the Bay Area’s Medivation (MDVN) 6/3/2016
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex (CLDX) Stock 6/3/2016
Novartis AG (NVS) Employees in Shanghai Get a New $1 Billion Home 6/2/2016
All Eyes Turn to Sarepta (SRPT) as BioMarin (BMRN) Shutters Its Kyndrisa Duchenne Program 6/2/2016
Roche (RHHBY) and Novartis AG (NVS) Gear Up to Battle Over Biosimilars 6/2/2016
Activist Investor Carl Icahn's Big Buy of Allergan (AGN) Shares Raises Questions of Influence 6/1/2016
2 Potentially Hot Biotech Stocks Currently Under $5 Per Share 6/1/2016
Why Intercept Pharma (ICPT) Just Became an Even More Attractive Takeover Target 6/1/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/31/2016
Bad News for AstraZeneca PLC (AZN) is Good News for Relypsa (RLYP) 5/31/2016
Gilead (GILD), Biogen (BIIB), Jazz Pharma (JAZZ) Subpoenaed as Feds Investigate Drugmaker-Charity Connections 5/27/2016
3 Biotech Stocks Flying High Under-the-Radar 5/27/2016
FORUM Pharma CEO Quits Amid Layoffs and a Possible Company Shutdown 5/27/2016
Titan Pharma (TTNP) Receives FDA Approval for the First Ever Implantable Device for Opioid Dependency 5/27/2016
Making Sense of Alnylam (ALNY)’s Recent Stock Surge 5/27/2016
Nine Bay Area Biotechs Vie to be the “Next Genentech (RHHBY)” 5/26/2016
Sarepta (SRPT) Rockets After the FDA Delays Ruling on DMD Drug 5/26/2016
Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million 5/25/2016
Amid Restructuring and Lawsuits, Novartis AG (NVS) Indicates It Might Sell $14 Billion Roche (RHHBY) Stock Without a Premium 5/25/2016
Eli Lilly (LLY) Projects 20 New Product Launches in 10 Years with 20 Possible Expansions 5/25/2016
Amid Shareholder Pressure, Bayer AG (BAYZF) Makes Formal $62 Billion Bid for Monsanto  (MON) 5/24/2016
Bicycle Therapeutics Sets Up Shop in Massachusetts, Taps a New President and CBO 5/24/2016
Arbor Pharma Shells Out $467 Million for Bay Area’s Restless Leg Drug Company XenoPort (XNPT) 5/24/2016
Sarepta (SRPT) Who? This DMD Drugmaker Might be a Better Buy for Investors 5/23/2016
Amgen (AMGN) Researchers Discover Gene that Cuts Heart Attack Risk 5/23/2016
13 Massachusetts Cancer Biotechs Looking to Shake Things Up at ASCO in June 5/20/2016
Genentech (RHHBY) Nabs FDA Approval of First New Bladder Cancer Drug in 30 Years 5/20/2016
Bill & Melinda Gates Foundation Gets $86.7 Million Windfall After Taking a $5 Million Stake in Anacor (ANAC) Three Years Ago 5/20/2016
Agios (AGIO), Celgene (CELG) Hammer Out $1 Billion+ Metabolic Immuno-Oncology Deal 5/19/2016
MacroGenics (MGNX) Wrangles Cancer Deal Worth $755 Million Out of Johnson & Johnson (JNJ) 5/19/2016
Eli Lilly (LLY) and Regeneron (REGN) Tips: How to Find Your First Biopharma Job Right Out of College 5/19/2016
AstraZeneca PLC (AZN)'s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017 5/18/2016
Delving Into Pfizer (PFE)’s Anacor (ANAC) Acquisition Strategy and Its Impact on Regeneron (REGN) 5/17/2016
Bay Area's Relypsa (RLYP) Falls on Unimpressive Veltassa Script Data 5/17/2016
In Another Small Deal, Pfizer (PFE) Slams Down $5.2 Billion for Bay Area Drugmaker Anacor (ANAC) 5/17/2016
After Heart Drug Flunks Phase II Study, Trevena (TRVN) Makes Strategic Pivot to Focus on Pain Drugs 5/16/2016
Pfizer (PFE) Joins 24 Other Companies in Blocking Use of 7 Drugs for Lethal Injections 5/16/2016
Pfizer (PFE) Shows Off TRUMENBA Data from Two Large-Scale Phase III Trials 5/13/2016
Only Days After a Follow-On Offering, San Diego's Sophiris Bio (SPHS) Hires Oppenheimer to Explore Strategic Options 5/13/2016
Regeneron (REGN) CEO Says Critique of the Company's New Cholesterol Lowering Therapy Was Non-Scientific 5/13/2016
Why Pfizer (PFE)'s Pipeline and Products May Have an Edge Over Merck & Co. (MRK) 5/13/2016
GlobeImmune (GBIM) Considers Sales or Closure After Bleak Q1 Financials 5/13/2016
Bayer (BAY) Rumored to be Exploring Bid for $40 Billion Seed Company Monsanto  (MON) 5/12/2016
Massachusetts’ PixarBio Hiring at New Jersey Site to Respond to Opioid Crisis 5/12/2016
Bay Area's ChemoCentryx (CCXI) Inks $85 Million Deal With Vifor Pharma for Lead Product Candidate 5/12/2016
Dermatology Company Galderma Laboratories Expands HQ and Brings on 400+ Jobs in Support of Nine New Product Launches 5/12/2016
Seattle-Based Omeros (OMER) Beefs Up Salesforce as Cataract Surgery Drug Sales Take Off in Q1 5/11/2016
Medivation (MDVN) Takeover Saga Takes Another Turn, Rumored to Open Books to Amgen (AMGN) and Pfizer (PFE) 5/11/2016
Pulitzer Prize Author of “Emperor of All Maladies” Launches Biotech Startup Vor BioPharma in Boston 5/11/2016
Hours After Debuting Biotech Startup Vor BioPharma, PureTech Launches Alivio Therapeutics 5/11/2016
EPIRUS Biopharma to Slash 40% of Workforce, Suspend Lead Clinical Program and Replaces CEO 5/11/2016
Gilead (GILD) CEO Targets Cancer Acquisitions with $21 Billion Cash Pile 5/10/2016
Facebook's Oculus Rift Developer Resigns to Work on Wearable MRI Startup 5/9/2016
Incyte (INCY) Buys Ariad (ARIA)'s EU Operations and Iclusig Rights for $140 Million Upfront 5/9/2016
Sanofi (SNY) Heats Up Medivation (MDVN) Bid With Letter Threatening a Hostile Takoever 5/6/2016
Pfizer (PFE) Turns to WAVE Life Sciences (WVE) for Drug Discovery in Deal Worth $911 Million 5/6/2016
Startup Hera BioLabs Builds $1.8 Million Headquarters and Creates 23 New Jobs 5/6/2016
Amid Restructuring and Rumors of a LabCorp (LH) Merger, CRO INC Research (INCR) Lays Off 175 5/5/2016
2 Biotechs Investors Should Pick Up Before Key PDUFA Dates 5/5/2016
Biogen (BIIB)'s Hemophilia Spinoff Suggests M&A Activity Could Be On the Horizon 5/5/2016
Bay Area’s Medivation (MDVN) Shores Up Defenses as Pfizer (PFE) Rumored to Join Sanofi (SNY) in Acquisition Bid 5/4/2016
Biogen (BIIB) Spinning Off Hemophilia Business to Focus On Neurological Disorders 5/4/2016
3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio (BLUE) 5/4/2016
Amid Hemophilia Spinoff, Biogen (BIIB)’s Head of Strategy Returns to Bain Capital 5/4/2016
Pfizer (PFE) Rumored to be Selling Its Hospira Pumps Division, With Smiths Group, Fresenius SE and Pamplona Capital Bidding 5/3/2016
AstraZeneca PLC (AZN) to Cut Jobs in $1.5 Billion Cost-Cutting Move, Will Double Down on Cancer 5/2/2016
EMD Serono Expansion to Create 150 New Jobs in Massachusetts 5/2/2016
Startup Homology Medicines Launches With $43 Million Series A, To Be Led By Three Former Shire (SHPG) Execs 5/2/2016
Abbott (ABT) Tries to Back Out of $5.8B Alere (ALR) Deal, But Alere Says It’s Still On 5/2/2016
Medivation (MDVN) Says No! to Sanofi (SNY)'s $9.3 Billion Hostile Bid 4/29/2016
AbbVie (ABBV) Pays $5.8 Billion+ for Bay Area's Stemcentrx, Which Has Ties to Paypal and SpaceX Investors 4/29/2016
AstraZeneca PLC (AZN) Stays Mum on M&A, Says “No Comment” to Medivation (MDVN) Bid 4/29/2016
Sanofi (SNY) Makes Hostile $9.3 Billion Bid for Bay Area’s Medivation (MDVN) 4/29/2016
Abbott (ABT)'s $25 Billion Bid for St. Jude Medical (STJ) Raises Questions About Pending Alere (ALR) Deal 4/28/2016
Anavex (AVXL)’s Alzheimer’s Drug a Possible Game Changer After Patients Reported Remarkable Positive Response 4/28/2016
The M&A Rumor Mill Points to Gilead (GILD) Acquiring Intercept Pharma (ICPT) 4/28/2016
Amid Positive First Quarter Financials, GlaxoSmithKline (GSK) Boss Expects a Late 2016 Replacement 4/27/2016
Rounding Up the Experts’ Thoughts on What's Next for Sarepta (SRPT)'s DMD Drug 4/27/2016
Rumors Surface Again About AstraZeneca PLC (AZN), Sanofi (SNY) or AbbVie (ABBV) Acquiring Medivation (MDVN) 4/27/2016
FDA Panel’s 7-6 Vote Against Sarepta (SRPT)’s DMD Drug Underlines Battle Between Science and Patient Advocates 4/26/2016



//-->